(Q39009865)

8 September 2017

1 reference

title

Evidence-based pharmacotherapy of treatment-resistant unipolar depression (English)

1 reference

8 September 2017

0 references

2

Siegfried Kasper

0 references

Markus Dold

object named as

Markus Dold

series ordinal

1

0 references

publication date

16 November 2016

1 reference

International Journal of Psychiatry in Clinical Practice

8 September 2017

1 reference

8 September 2017

21

1 reference

8 September 2017

13-23

1 reference

8 September 2017

1

1 reference

Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review

8 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

High dose tranylcypromine therapy for refractory depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Patients With Severe Depression May Benefit From Buspirone Augmentation of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Role of lithium augmentation in the management of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

The thyroid-brain interaction in thyroid disorders and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Risk factors for treatment resistance in unipolar depression: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Cross-national epidemiology of DSM-IV major depressive episode

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

International consensus study of antipsychotic dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

National trends in second-generation antipsychotic augmentation for nonpsychotic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Suicide risk in patients treated with lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Irritable mood in adult major depressive disorder: results from the world mental health surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Antidepressant combination for major depression in incomplete responders--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Lithium toxicity profile: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Which antidepressants have demonstrated superior efficacy? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or ag

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Empirical testing of two models for staging antidepressant treatment resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Adjunctive lithium treatment in the prevention of suicidal behavior in patients with depression and comorbid personality disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Early switch strategy in patients with major depressive disorder: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Treatment resistant depression: methodological overview and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Switching antidepressant class does not improve response or remission in treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Predictors of efficacy in lithium augmentation for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

The size and burden of mental disorders and other disorders of the brain in Europe 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

Treatment-resistant Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651501.2016.1248852

10.1080/13651501.2016.1248852

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference

PubMed ID

27848269